

To,  
The Manager  
Listing department,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai- 400 051  
Maharashtra

**Subject: Outcome of the Board Meeting held on Monday, 7<sup>th</sup> day of February, 2022 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015**

**Ref.: Symbol- PAR, ISIN: INE04LG01015**

Dear Sir/Madam,

The meeting of Board of Directors of the Company held on **Monday, 7<sup>th</sup> day of February, 2022** at **4:00 PM** through Video Conferencing ("VC") mode inter alia transacted the following business:

Item No.	Outcomes
1.	After the recommendation of Audit Committee, the Board of Directors considered, approved and took on record the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended on 31 <sup>st</sup> December, 2021 along with Limited Review Report given by CA Vipul V. Dhamsania, Partner of V Dhamsania & Associates, Chartered Accountants having valid Peer Review Certificate, Statutory Auditor of the Company. The financial results were reviewed by Audit Committee at its meeting and Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Certificate of correctness was placed before the Board Meeting as attached herewith.  (Limited Review Report is attached as Annexure)
2.	The Board considered and approved the drafts of advertisements to be published in newspapers regarding Unaudited Standalone Financial Results of the Company for the quarter and nine months ended on 31 <sup>st</sup> December, 2021. The Board decided to publish the said advertisements in the Economic Times & Navgujarat Samay.
3.	The Board took note of Investor grievances report for the quarter ended 31 <sup>st</sup> December, 2021
4.	The Board took note that the company has paid earned leave to the employees of Rs. 6.21 Lakh for the calendar year 2021 start from January 2021 to December 2021.
5.	The Board took note and review the Corporate Governance Report of the Company for the quarter ended 31 <sup>st</sup> December, 2021.
6.	The Board of Directors other than independent Directors evaluated the performance of present Independent directors of the Company, find proper and qualified.
With the permission of the Chairman of the Company, following other matter were considered	
7.	Mr. Jignesh V. Savani Director & CEO of the Company has informed the Board members regarding Company's upcoming renovation of the Manufacturing Block 1 for APIs which is well planned in two phases put for the discussion and approved by the Board so that he has informed board members that Phase 1 will be start shortly without affecting current production process and qualities, which will increase the efficiency of production.





DRUGS AND CHEMICALS LIMITED

**Registered Office :**

815, Nilamber Triumph, Gotri-Vasna Road, Vadodara - 390 007. Gujarat (INDIA).  
Ph. : +91-265-2991021 / 2991022

**Email :** admin@pardrugs.com

**CIN No. :** L24117GJ1999PLC035512

www.pardrugs.com

Further, with reference to our intimation dated 28<sup>th</sup> December, 2021 and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and amendment made time to time till date and according to Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the trading window for trading in securities of the Company will be opened after 48 hours of declaration of the attached financial result for Designated persons, Designated employees and their Immediate relatives.

The Board Meeting was commenced at 4:00 PM and concluded at 05:08 PM.

Kindly take on the record and acknowledge the receipt.

Yours Faithfully,

**For PAR DRUGS AND CHEMICALS LIMITED**

**(Sanket B. Trivedi)**

**Company Secretary & Compliance Officer**



**Annexure:**

1. Limited Review Report on standalone un-audited Quarterly and nine month ended financial results for the quarter ended 31<sup>st</sup> December, 2021
2. Standalone Un-Audited Financial Results for the Quarter and Nine Month Ended 31<sup>st</sup> December, 2021
3. Certificate of Correctness of financial Statement







